“We are all about finding diseases early. Our current focus is on cancer. If you can find it early your […]
GeneNews Limited (TSX: GEN) has announced that the company will change its name to “StageZero Life Sciences, Ltd.” The Company […]
Nothing is more important in life than your health. The early detection of diseases like cancer is improving each decade, […]
StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which was validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer. Further validation of Aristotle is currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.